# A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)

> **NCT05150938** · — · COMPLETED · sponsor: **Bayer** · enrollment: 5737 (actual)

## Conditions studied

- Treatment of Venous Thromboembolism in Cancer Patients

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Low molecular weight heparin (LMWH)
- **DRUG:** vitamin K antagonist (VKA)
- **DRUG:** other NOACs

## Key facts

- **NCT ID:** NCT05150938
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-18
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-02-28
- **Target enrollment:** 5737 (ACTUAL)
- **Last updated:** 2023-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05150938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05150938, "A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05150938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*